Search - tctmd.com

Displaying 21 - 40 of 312

Sort: Relevancy | Date

Presentation TCT 2025

Emerging Therapies: The Role of GLP-1 Agonists and SGLT2 Inhibitors in PAD/CLTI Management. Impact on the Guidelines

Presenter: Marc P. Bonaca

October 27, 2025

Presentation TCT 2025

TCT 760: SGLT2 Inhibitors Reduce Acute Kidney Injury and Improve Survival in Diabetic Patients Undergoing Transcatheter Aortic Valve Replacement

Presenter: Priyesh Thakurathi

October 27, 2025

Presentation TCT 2025

TCT 755: Impact of SGLT2 Inhibitors on Outcomes After TAVR: A Real-World Propensity-Matched Analysis

Presenter: Salman Zahid

October 27, 2025

Presentation TCT 2025

TCT 748: Effects of SGLT2 Inhibitors on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus Undergoing Transcatheter Mitral Valve Repair: A Propensity-Matched Analysis

Presenter: Mahmoud Abdelnabi

October 25, 2025

Presentation TCT 2025

TCT 749: Renal Protective Effects of SGLT2 Inhibitors After Transcatheter Mitral Valve Repair in Patients with Type 2 Diabetes Mellitus: A Propensity-Matched Retrospective Analysis

Presenter: Mahmoud Abdelnabi

October 25, 2025

After Acute HF Admission, Specialist Care Tied to Better Long-term Outcomes

News Daily News

After Acute HF Admission, Specialist Care Tied to Better Long-term Outcomes

October 07, 2025

Too Few HF Patients on Guideline-Directed Medical Therapy in VA System

News Conference News HFSA 2025

Too Few HF Patients on Guideline-Directed Medical Therapy in VA System

Yael L. Maxwell

October 06, 2025

Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74

News Conference News HFSA 2025

Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74

Yael L. Maxwell

September 30, 2025

CCM-D Delivers Safe, Effective Integrated Therapy in HFrEF

News Conference News HFSA 2025

CCM-D Delivers Safe, Effective Integrated Therapy in HFrEF

Yael L. Maxwell

September 29, 2025

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

News Conference News ESC 2025

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

Michael O'Riordan

September 01, 2025

Starting SGLT2 inhibitors in the Hospital for Acute HF Gains Support

News Conference News ESC 2025

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

August 30, 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

AI-Supported Coaching Shows Promise for Improving Glycemic Control

News Daily News

AI-Supported Coaching Shows Promise for Improving Glycemic Control

August 25, 2025

What’s Going to Be Hot at ESC Congress 2025?

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

HF Risks Stick Around Even When Ejection Fraction Improves

News Daily News

HF Risks Stick Around Even When Ejection Fraction Improves

August 01, 2025

Cardiac Biomarkers Equally Apt to Rise in COVID-19, Influenza

News Daily News

Cardiac Biomarkers Equally Apt to Rise in COVID-19, Influenza

July 25, 2025

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

July 24, 2025

Presentation NY Valves 2025

Impact of SGLT2 Inhibitors on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement

Presenter: Tamari Lomaia

June 26, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.